Advertisement

Topics

Human Soluble Receptor for Advanced Glycation End Products (sRAGE) for Treating Vascular Disease, Injury, or Inflammation

19:00 EST 22 Feb 2012 | NIH

The receptor for advanced glycation end products (RAGE) is a protein implicated in the development of vascular hyperplasia and in atherogenesis. RAGE is a cell surface protein that triggers signaling pathways leading to inflammation and RAGE-stimulated inflammation can contribute to adverse inflammatory conditions, such as atherosclerosis and arterial restenosis (a serious pathological complication that can follow surgical cardiovascular interventions like angioplasty).

Researchers at the National Institute on Aging (NIA) have developed methods to produce a soluble receptor for advanced glycation end products (sRAGE) in mammalian cells and the use of sRAGE for the treatment of vascular diseases and disorders, given that sRAGE has mammalian post-translational modifications. Further, sRAGE has been used to treat arterial restenosis and atherosclerosis in animal models. sRAGE, is used as a therapeutic agent that is believed to act as a decoy to diminish RAGE-dependent signaling, thereby attenuating inflammation and pathogenic consequences. sRAGE also has been associated with anti-mitotic effects.

IC: 
NIA
NIH Ref. No.: 
E-165-2011/0
TAB No: 
TAB-2380
Advantages: 
  • Greater than 1000-fold increased potency over sRAGE produced in insect cells
  • Treatment methods claimed by the patent span a wide array of indications
  • Readily scalable production of materials utilized in treatment regimens
  • Routes of administration of sRAGE include intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal, epidural, topical, percutaneous, subcutaneous, transmucosal, intranasal, and oral
Applications: 
  • Prevention of vascular inflammation
  • Treatment for any disease, disorder, condition, injury, or inflammation that primarily affects the blood vessels
  • Treatment of vascular diseases such as atherosclerosis, restenosis, angina, myocardial ischemia, or any condition associated with cardiovascular inflammation
  • Treatment of Alzheimer's disease
Development Status: 
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Provider Technology ID: 
2380
Updated On: 
Jun 29, 2017
Date Published: 
Thursday, February 23, 2012
Provider Classifications: 
Patent Application: 
14/368,374
PCT/US2013/020103
61/582,574
Publications: 
2016-03-28 00:00:00
2016-03-28 00:00:00
Patent Authority: 
US
PCT
US
Patent Number: 
9,175,062
Licensing Contacts: 
LPM Address: 
  --
United States
Lead Inventor: 
Inventor IC: 
NIA
NIA
NIA
NIA
NIA
NIA
NIA
NIA
NIA
Inventor Lab URL: 
https://irp.nih.gov/pi/edward-lakatta
http://www.grc.nia.nih.gov/branches/lcs/cgtu.htm
LPM FIrst Name: 
Richard
LPM Last Name: 
Girards
LPM Address: 
BG 9609 RM 1E508 9609 MEDICAL CENTER DR
LPM City: 
Rockville
Inv Is lead: 
LPM Zip: 
20850-9702
LPM State: 
MD
LPM Phone: 
240-276-6825
LPM Suffix: 
J.D., M.B.A.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
240-276-5504
DTDT Classification: 
Internal Medicine
Therapeutics
Cardiology
Other
Anti-Inflammatory (including Autoimmune)
Cardiovascular Disease
Central Nervous System
Early-stage
DTDT Description: 
Internal Medicine
Internal Medicine - Therapeutics
Internal Medicine - Therapeutics - Cardiology
Internal Medicine - Therapeutics - Cardiology: Other
Internal Medicine - Therapeutics: Anti-Inflammatory
Cardiovascular Disease
Central Nervous System
Early-stage
Pat Filing Date: 
2014-06-24
2013-01-03
2012-01-03
Patent Issue Date: 
2015-11-03
Development Stage Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

The National Institute on Aging, Laboratory of Cardiovascular Science, seeks licensing partners and statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize sRAGE.

E Number Only: 
E-165-2011
Inventor First Name: 
Li
Edward
Sungha
Hyun-Jin
Wen
Natalia
Rui-ping
Mark
Ismayil
Inventor Last Name: 
Lin
Lakatta
Park
Tae
Wei
Petrashevskaya
Xiao
Talan
Ahmet

Original Article: Human Soluble Receptor for Advanced Glycation End Products (sRAGE) for Treating Vascular Disease, Injury, or Inflammation

NEXT ARTICLE

More From BioPortfolio on "Human Soluble Receptor for Advanced Glycation End Products (sRAGE) for Treating Vascular Disease, Injury, or Inflammation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Vascular
Vascular relates to blood vessels (Oxford Medical Dictionary) and can be used to describe the supply of blood, a disease affecting the blood vessels or molecules associated with these structures. For example, <!--LGfEGNT2Lhm-->atherosclerosis ...